Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTSVJM)

• Drug Name: CJM112 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Phase 2	[1]
Chronic plaque psoriasis	EA90.0	Phase 1/2	[2]
Multiple myeloma	2A83	Phase 1	[3]
Plaque psoriasis	EA90.0	Phase 1	[4]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]

• Cross-matching ID: TTD Drug ID: DMTSVJM

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-17 (IL17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brodalumab	DMASDQ6	Plaque psoriasis	EA90.0	Approved	[6]
Bimekizumab	DMR9TF1	Plaque psoriasis	EA90.0	Approved	[4]
Ixekizumab	DMXW92T	Plaque psoriasis	EA90.0	Approved	[7]
CNTO-6785	DM6RQXB	Rheumatoid arthritis	FA20	Phase 2	[8]
ABT-122	DM23UQ9	Psoriatic arthritis	FA21	Phase 2	[9]
COVA322	DM824EG	Psoriasis vulgaris	EA90	Phase 1/2a	[10]
SHR-1314	DMADNY3	Plaque psoriasis	EA90.0	Phase 1/2	[4]
ABBV-257	DMCZI8L	Rheumatoid arthritis	FA20	Phase 1	[2]
ALX-0761	DMJ8ACF	Psoriasis vulgaris	EA90	Phase 1	[10]
SCH-900117	DM7A6R5	Rheumatoid arthritis	FA20	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-17 (IL17)	TTG0MT6	IL17_HUMAN	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT02998671) Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
• [8] Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
• [9] DOI: 10.1136/annrheumdis-2015-eular.4042
• [10] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [11] Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76.